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Aims Single-chamber (VR-ICD) and subcutaneous (S-ICD) implantable cardioverter-defibrillators are effective to protect
patients against sudden death but expose them to higher risk of inappropriate shock (IS). We sought to quantify
the annual rate and influencing factors of ISs in VR- and S-ICDs from the literature.
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Methods
and results
PubMed, Embase, and Cochrane Library were searched for full text articles with IS rates. Poisson distribution
estimated proportion of patients with ISs; rates were annualized based on follow-up duration. Random effects
meta-analysis accounted for study-to-study variation. Out of 3264 articles, 16 qualified for the meta-analysis.
Across studies, 6.4% [95% confidence interval (CI) 5.1–7.9%] of patients received an IS per year. Meta-regression
analyses demonstrated that IS rates were lower in more recent studies [rate ratio (RR) per year: 0.93, 95% CI:
0.87–0.98; P= 0.01] and trended lower in studies with longer follow-up (RR per year: 0.78, 95% CI: 0.60–1.01;
P= 0.06). Use of S-ICDs (RR: 1.81, 95% CI: 0.86–3.81; P= 0.12) and ventricular tachycardia zone programmed on
(RR: 1.13, 95% CI: 0.65–1.97; P= 0.66) were not associated with a significantly increased change in risk. The IS rate
observed in one of the more recent studies was significantly lower than predicted after accounting for covariates
(RR: 0.29, 95% CI: 0.14–0.60; P< 0.001).
...................................................................................................................................................................................................
Conclusions A comprehensive review of the literature shows that 6.4% of patients with ICDs experienced their first IS annually.
One of the 16 studies was better than predicted with the lowest reported rate (1.9%) and could not be explained
by timing of the study or other covariates.
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Introduction
The pivotal trials demonstrating effective prevention of sudden
cardiac death with implantable cardioverter-defibrillators
(ICDs) for both secondary and primary prevention were estab-
lished primarily by devices without atrial leads.1–5 ICDs with
right atrial leads (i.e. dual-chamber) were developed to enhance
rhythm diagnosis (ventriculo-atrial association) with the intent
to reduce the inappropriate shock (IS) rate for atrial fibrillation
(AF) and supraventricular tachycardias as well as to provide
atrial rate and atrioventricular conduction support, when clinic-
ally indicated.
* Corresponding author. Tel: þ41 91 805 3340; fax: þ41 91 805 3213. E-mail address: angelo.auricchio@cardiocentro.org
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A recent retrospective cohort study of admission in the National
Cardiovascular Data Registry’s ICD registry from 2006 to 2009 found
that among patients receiving an ICD for primary prevention without
a pacing indication, the use of a dual-chamber device compared with
a single-chamber device was associated with a higher risk of device-
related complications and similar 1 year mortality and hospitalization
outcomes.6 Additionally, a recent systematic assessment of ISs com-
paring dual-chamber ICDs with single-chamber devices revealed no
clear superiority of dual-chamber ICDs vs. single-chamber in reduc-
ing ISs.7 Thus, an atrial lead is not recommended for a substantial pro-
portion of ICD-indicated patients.8
Since the publication of the ICD landmark trials,1–4 significant
technological advances have occurred and device programming has
substantially changed which may have influenced the IS rate.
However, it is unknown whether the IS rate in single-chamber ICDs
(VR-ICDs) has changed over time. In light of all of the above consid-
erations, we sought to quantify the annualized frequency of first ISs
among VR-ICDs and subcutaneous ICDs (S-ICDs) and to determine
influencing factors associated with their occurrence through a sys-
tematic review and meta-analysis. Furthermore, we assessed whether
the annualized rate of appropriate shocks in these patients changed
over time.
Methods
Search strategy
The systematic review and meta-analysis were conducted according to
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement.9 A systematic search of PubMed (Medline),
Embase, and Cochrane Library was performed to identify articles with
VR-ICD or S-ICD IS rates published through July 2015. The following
Boolean search terms were utilized: ‘implantable defibrillator OR ICD’
AND ‘shock OR shocks OR therapy’ AND inappropriate.
Study selection and data extraction
Search criteria and methodology were approved by all authors. Titles and
abstracts retrieved in the search were reviewed, and observational and
comparative studies reporting IS rates in ICDs were selected. Studies
were included if results reported VR-ICD or S-ICD IS rates, were in the
English language, and included human subjects >_18 years of age. Case re-
ports, review articles, abstracts, and editorials were excluded, as were
studies with <100 patients with single chamber/subcutaneous devices
and studies with <6 months of follow-up. In the event that there were
multiple publications from the same study, the latest study with the most
complete data available was selected, and the other publications were
not used in order to avoid overlapping cohorts. Final determination of
article eligibility was assessed by two authors (J.H.H. and D.H.F.). For
included studies, only data on VR-ICD/S-ICD patients were extracted.
Extracted data included: number of patients, follow-up duration, IS rate,
appropriate shock rate, proportion with AF at baseline, use of a slow VT
zone, and prolonged detection. Data were extracted by one author
(D.H.F.) and were reviewed by additional authors (T.R., J.H.H., and A.A.).
Meta-analysis
Meta-analysis methods provided a structured, model-based way to com-
bine information from multiple studies. To estimate the annual first IS
rate among patients implanted with a VR-ICD or S-ICD, we used
random-effects Poisson regression. This method models the number of
patients with a first IS via a Poisson distribution, where the expected num-
ber of patients with an IS is a function of the IS rate and the total number
of years of patient follow-up observed in the study. Modeling patient
counts based on the total years of follow-up captures the fact that a study
with more patients or with longer average follow-up per patient is ex-
pected to observe more patients with an IS than a shorter or smaller
study with the same annual rate. We modelled study-to-study variation in
the number of patients with an IS that exceeds the degree of variation ex-
pected with the Poisson distribution with normally distributed random ef-
fects. These methods were also used to estimate the rate of first
appropriate shocks.
Meta-regression was used to examine how study-level factors contrib-
ute to differences in IS rates. Average duration of follow-up and study
timing were assessed for their relationships to IS rate. When the study
was conducted served as a proxy for a collection of treatment changes
over time (e.g. improved ICD technology, programming strategies, pa-
tient selection) and was measured by the middle year of study enrolment.
We further examined how IS rates differ by the study’s ICD programming
(with vs. without a VT zone) and by device type (VR-ICD vs. S-ICD). To
assess whether these factors were sufficient to explain each study’s IS
rate, we tested whether a study’s observed rate was in agreement with
the model-estimated expected IS rates based on all other studies’ data
given the study’s mean follow-up, middle enrolment year, ICD program-
ming, and device type.
Statistics
The Poisson meta-analysis with normal random effects was performed
with the metafor package for R statistical software.10 Heterogeneity was
assessed with the I2 index,11 expressing the proportion of variation that is
not explained by Poisson sampling variability. The IS rate was modelled
on the log scale as a linear combination of the regression factors. P-values
<0.05 were considered statistically significant.
Results
A total of 3264 articles were retrieved after excluding duplicates.
After excluding 3095 articles for not meeting inclusion/exclusion cri-
teria, 169 articles remained to be assessed for eligibility. Following as-
sessment of the full-text articles, 153 were excluded for reasons such
as: shocks were not separated by device type, the device type was
not specified, or rates of inappropriate therapy (rather than just
What’s new?
• Our study showed a relatively constant annual appropriate
shock rate of 5.8% and an annual inappropriate shock rate of
6.4% which later progressively reduced over time, and signifi-
cantly dropped to 1.9% in one of the more recent studies.
• Meta-regression analyses demonstrated that inappropriate
shock rates were lower in more recent studies and trended
lower in studies with longer follow-up.
• Use of subcutaneous implantable cardioverter-defibrillators
and ventricular tachycardia zone programmed on were not
associated with a significantly increased change in risk.
• These observations call for further investigation in the contem-
porary outcomes of heart failure patients and in those indi-
cated for an implantable cardioverter-defibrillator.
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shocks) were given, and two studies were excluded due to reporting
IS rates for SVT only.12,13 This left us with 16 studies to be included in
the analysis (Figure 1, Table 1).
The final population for the meta-analysis included 6470 patients
with 14 696 patient-years cumulative follow-up (mean 919 patient-
years). Middle year of enrolment for the studies ranged from 1999
to 2011, with the average middle year of enrolment being mid-
way through 2005. Of the 16 studies included in the meta-analysis,
13 were VR-ICD studies and three were S-ICD studies. Thirteen
studies were prospective and three studies were retrospective.
Five of 16 studies reported percentage of VR-ICD or S-ICD
patients with AF. A total of 926 patients received ISs across the
16 studies.
A random effects Poisson meta-analysis estimated an annualized IS
rate of 6.4% (95% CI 5.1–7.9) with substantial variability between
studies (Figure 2A). The I2 statistic was 90.1%. A meta-regression ana-
lysis adjusting for mean follow-up time and the middle year of enrol-
ment explained a statistically significant degree of variability
(P= 0.04), but the heterogeneity remained high (I2=85.5%). This
meta-regression model found that studies with longer mean follow-
up had lower annualized IS rates. The annualized rate was estimated
to decrease by a factor of 0.76 (95% CI 0.60, 0.95, P= 0.02) for each
additional year of mean follow-up. Each additional year in a study’s
middle year of enrolment was associated with a reduction in the IS
rate by a factor of 0.94 (95% CI 0.89, 1.0, P= 0.04), with studies con-
ducted more recently having lower IS rates than those conducted far-
ther in the past (Figure 3). A more detailed meta-regression model
included device type and slow VT zone programming, study factors
that were reported across all studies (Table 2). AF prevalence was
not reported in all studies and prolonged detection was only used in
a single study. Therefore these variables were not included in the
model. Subcutaneous ICD studies were estimated to have an IS rate
1.81 (95% CI 0.86, 3.80, P= 0.12) times the transvenous shock rate,
but the difference was not statistically significant. Use of a slow VT
zone was estimated to result in an IS rate 1.13 (95% CI 0.65, 1.97,
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Figure 1 PRISMA flow diagram. Diagram depicting systematic
review process, following the PRISMA approach.
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Table 1 Studies included in meta-analysis
Study Publication
year
Device
type
Randomization No.
patients
Follow-up
(months)
% AF VTrate cutoff
(lowest)
Slow
VT Rx
MADIT II4 2002 VR-ICD – 405 20 NR 160 bpma Yes
SCD HeFT2 2005 VR-ICD – 808 45.5 NR NR No
Sacher et al.14 2006 VR-ICD – 196 21 NR 170 bpma Yes
DATAS15 2008 VR-ICD – 111 15.6 NR 167 bpm Yes
Kleemann et al.16 2011 VR-ICD – 596 62.5 NR 167 bpm Yes
Gonzalez-Enrıquez et al.17 2012 VR-ICD – 332 12 NR NR No
Yang et al.18 2012 VR-ICD – 136 29 NR 160 bpm Yes
RIGHT19 2012 VR-ICD VITALITY 2 507 18.3 NR 150 bpm Yes
Medtronic 504 18.3 NR 150 bpm Yes
Olde Nordkamp et al.20 2012 S-ICD – 118 18 11 NR No
Deyell et al.21 2013 VR-ICD – 354 30 NR NR Yes
ECOST22 2013 VR-ICD Active 161 24.2 NR 150 bpm Yes
Conventional 141 24.2 NR 150 bpm Yes
S-ICD IDE23 2013 S-ICD – 314 11 15 NR No
OPTION24 2014 VR-ICD – 223 23.4 11 170 bpm Yes
DECREASE25 2015 VR-ICD Conventional 112 12 NR 171 bpm Yes
Progressive 120 12 NR 187 bpm No
EFFORTLESS26 2015 S-ICD – 581 21.4 17 NR No
PainFree SST27 2015 VR-ICD – 751 24 22 167 bpm Yes
NR, not reported.
aAssumed rate, lowest rate reported in manuscript.
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P= 0.66) times higher, which was also not statistically significant. The
addition of these variables did not significantly reduce the unex-
plained heterogeneity (I2=82.4%). Using this model, the expected IS
rate for a 1-year study of transvenous single-chamber ICDs with a
slow VT zone with enrolment at the same time as the most recent
studies in this analysis is 5.3% (95% prediction interval from 2.5% to
11.4%).
Each individual study’s observed IS rate was compared with the ex-
pected rate based on this more detailed model estimated using the
results of all other studies. The observed and expected IS rates are
shown in Figure 2B along with their relative rate (observed/expected).
Two studies had rates that were statistically different from the ex-
pected rate after accounting for device type, VT zone programming,
mean follow-up duration, and middle enrolment year. The PainFree
SST study had a lower IS rate than expected (relative rate 0.287; 95%
CI 0.138, 0.596, P= 0.0008). The Vitality arm of the RIGHT study had
a higher IS rate than expected (relative rate 2.073; 95% CI 1.098,
3.915, P= 0.025).
Annualized inappropriate shock rate
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Sacher F et al., 2006
DATAS, 2008
Kleemann T et al., 2011
Gonzalez-Enriquez S et al., 2012
Yang JH et al., 2012
RIGHT-MDT, 2012
RIGHT-Vitality, 2012
Olde Nordkamp LR et al.,2012
Deyell MW et al., 2013
ECOST-Active, 2013
ECOST-Conventional, 2013
S-ICD IDE, 2013
OPTION, 2014
DECREASE-Conventional, 2015
DECREASE-Progressive, 2015
EFFORTLESS, 2015
PainFree SST, 2015
MADIT II, 2002
SCD HeFT, 2005
Sacher F et al., 2006
DATAS, 2008
Kleemann T et al., 2011
Gonzalez-Enriquez S et al., 2012
Yang JH et al., 2012
RIGHT-MDT, 2012
RIGHT-Vitality, 2012
Olde Nordkamp LR et al.,2012
Deyell MW et al., 2013
ECOST-Active, 2013
ECOST-Conventional, 2013
S-ICD IDE, 2013
OPTION, 2014
DECREASE-Conventional, 2015
DECREASE-Progressive, 2015
EFFORTLESS, 2015
PainFree SST, 2015
RE Model
0.000
0.00 0.05 0.10 0.15
Annualized Event Rate
0.20
Observed
Predicted
0.25
Study Name Observed and Predicted Inappropriate Shock Rates Relative Rate [95% Cl] p-value
0.050 0.100
Incidence Rate
0.150 0.200
0.076 [ 0.057 , 0.099 ]
0.046 [ 0.039 , 0.054 ]
0.068 [ 0.050 , 0.092 ]
0.090 [ 0.052 , 0.155 ]
0.078 [ 0.066 , 0.092 ]
0.052 [ 0.042 , 0.064 ]
0.088 [ 0.061 , 0.127 ]
0.079 [ 0.062 , 0.102 ]
0.124 [ 0.102 , 0.152 ]
0.085 [ 0.051 , 0.141 ]
0.076 [ 0.060 , 0.096 ]
0.031 [ 0.017 , 0.057 ]
0.053 [ 0.032 , 0.088 ]
0.142 [ 0.105 , 0.193 ]
0.053 [ 0.035 , 0.080 ]
0.107 [ 0.061 , 0.189 ]
0.033 [ 0.013 , 0.089 ]
0.046 [ 0.035 , 0.061 ]
0.019 [ 0.013 , 0.027 ]
0.064 [ 0.051 , 0.079 ]
0.522 ( 0.221 , 1.234) 0.1385
0.3546
0.6741
0.7217
0.8748
0.0865
0.2726
0.5850
0.0246
0.9707
0.7346
0.1753
0.8097
0.0996
0.8964
0.1127
0.3876
0.1105
0.0008
0.666 ( 0.282 , 1.574)
0.837 ( 0.366 , 1.917)
0.838 ( 0.318 , 2.213)
1.064 ( 0.492 , 2.299)
2.450 ( 0.879 , 6.825)
1.549 ( 0.709 , 3.384)
1.234 ( 0.881 , 2.621)
2.073 ( 1.098 , 3.915)
0.982 ( 0.366 , 2.633)
1.138 ( 0.538 , 2.407)
0.523 ( 0.205 , 1.335)
1.137 ( 0.400 , 3.235)
2.081 ( 0.870 , 4.976)
0.946 ( 0.410 , 2.181)
2.134 ( 0.837 , 5.442)
0.533 ( 0.128 , 2.225)
0.494 ( 0.208 , 1.174)
0.287 ( 0.138 , 0.596)
Annual Inappropriate
Shock Rate [95% Cl]
B
A
Figure 2 (A) Annualized inappropriate shock rate. Random effects Poisson meta-analysis depicting annualized inappropriate shock rate. In the
model, the expected number of patients with an inappropriate shock is a function of the inappropriate shock rate and the total number of years of pa-
tient follow-up observed in the study. (B) Observed vs. predicted inappropriate shock rates. A meta-regression analysis adjusting for mean follow-up
time, the middle year of enrolment, device type, and slow VT zone programming was used to calculate predicted inappropriate shock rates. Each indi-
vidual study’s observed (annualized) inappropriate shock rate was compared with the predicted rate. Results are shown as relative rates.
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To understand the appropriate shock rates for VR-ICD’s and
S-ICDs, a meta-analysis was also performed within a subgroup of the
16 studies that reported appropriate shocks. Seven studies with 3136
patients followed for 6631 patient-years were included. Three of the
studies were of S-ICDs. The annualized appropriate shock rate was
estimated at 5.8% (95% CI 5.3, 6.3) (Figure 4). The observed hetero-
geneity in appropriate shock rates was in line with that expected by a
Poisson distribution (I2=0.0%).
Discussion
The objective of this study was to systematically assess the annualized
rate of inappropriate and appropriate shocks in VR-ICDs. Our ana-
lysis covered approximately 15 years of clinical trials in which a VR-
ICD was used and the rate of IS was reported. To our knowledge,
this is the most comprehensive assessment of appropriate and in-
appropriate ICD shock rates to date. Our study showed a relatively
constant annual appropriate shock rate of 5.8% and an annual IS rate
of 6.4% which later progressively reduced over time, and significantly
dropped to 1.9% in one of the more recent studies. This study was
not designed nor had the intention of demonstrating that transve-
nous technology is superior to subcutaneous technology, nor that
one ICD brand is better than another one. Rather, our analysis dem-
onstrates that the rate of ISs, independently of the implantation ap-
proach used and manufacturer, has dramatically changed over time
and is continuously reducing. This is important, and in our opinion,
reassuring information for patients and families, general practitioners,
cardiologists, scientific societies, and regulators. Furthermore, one
may consider the single-chamber ICD an effective choice to protect
patients against sudden death without compromising safety at an ex-
cellent cost-effectiveness ratio.
This study expands the current understanding of the contempor-
ary outcome in terms of shock rate in patients receiving VR-ICDs. In
the early randomized clinical trials, incidence of inappropriate ICD
therapy widely ranged from 9% in the AVID trial1 and 11.5% in the
MADIT-II trial4, both reported during 2 year follow-up. This high inci-
dence has progressively decreased and currently ranges from a 1.9%
to 4.6% annualized rate as shown in the more recent prospective
studies27 and large observational studies.26 Several factors have con-
tributed to this impressive reduction in IS rate, including major tech-
nical improvements in lead manufacturing and lead performance
monitoring, prolongation of arrhythmia detection times, improved
discrimination algorithms, and greater adoption of remote monitor-
ing for patient management. Although our systematic review by de-
sign was not able to identify the factor(s) most likely contributing to
this remarkable reduction in annualized IS rate, the striking low IS
rate of the PainFree SST study provides some insights. PainFree SST
patients received a device in which a novel suite of detection algo-
rithms in conjunction with routine implementation of a proven pro-
gramming strategy was activated as default at the time of device
González-Enriquez S, et al., 2012
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ble is proportional to the inverse of the variance of the log-risk ratio.
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Table 2 Meta-regression analysis
Estimate (95% CI) P-value
Intercepta 0.047 (0.024, 0.090) <0.001
Middle enrolment year (per year) 0.93 (0.87, 0.98) 0.01
Mean follow-up (per year) 0.78 (0.60, 1.01) 0.06
S-ICD vs. Transvenous 1.81 (0.86, 3.80) 0.12
VT zone programmed (Yes vs. No) 1.13 (0.65, 1.97) 0.66
aIntercept for 2011 Middle Enrolment Year, 1 Year Mean Follow-up,
Transvenous ICD, with no VT Zone programmed.
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implantation. A recent historical comparison of a prospective data-
base found that the use of SST algorithms in new generation CRT-Ds
significantly reduced ISs compared with standard CRT-Ds without
the algorithms.28 This combination of algorithms and programming
resulted in an annualized IS rate of 1.9% for single-chamber ICDs in
the PainFree SST study, which was by far lower than the 5% probabil-
ity and the 3% probability of inappropriate therapy in the MADIT-
RIT29 and ADVANCE III studies30, respectively. Notably, the
MADIT-RIT study included only dual-chamber or triple-chamber
ICDs indicated for primary prevention of sudden death, and the pa-
tients had a lower prevalence of AF than the PainFree SST study.
The progressive reduction in IS rates has not been paralleled by a
similar remarkable reduction in the annualized appropriate shock
rate. This indicates that, despite major advancements in heart failure
therapy and patient management over the last decade, the risk of re-
peated life-threatening arrhythmias in VR-ICD patients has mostly re-
mained unchanged. Conversely, technology and device programming
have effectively helped in maximizing the benefit of ICDs. Repeated
or multiple shocks are painful, psychologically devastating, possible
sources of aggravation of cardiac function, and costly due to hospital-
ization subsequent to ICD firing.6,31–33 Additionally, a significant asso-
ciation between ICD shock and mortality has been demonstrated,32
although the level of association seems to be stronger for appropri-
ate shocks.33
By reducing the burden of ISs, one may expect a substantial reduc-
tion in health care resource utilization and in the cost-effectiveness
ratio, as well as increased patient quality-of-life31 and longevity.33
Although these important benefits are common to single-, dual-, and
triple-chamber ICDs, there are additional benefits specific to single-
chamber ICDs. Dual-chamber devices are more costly for initial
implant, are associated with an increased risk of device-related
in-hospital complications,6 require a slightly longer follow-up visit,34
and have a greater risk of generator depletion,35 all of which are
associated with increased costs compared with VR-ICDs. Although
further benefit may be expected by the use of an S-ICD, in our study
this type of device was estimated to have a non-statistically significant
IS rate 1.81 times the transvenous shock rate. However, a recently
presented EFFORTLESS analysis showing an annual IS rate of 3.7% of
985 subjects with S-ICDs followed to 3.1 years suggests that this rate
may be improving.36 Also, upcoming modifications to S-ICD devices
that include a new T-wave oversensing algorithm and/or a 9 Hz filter
are expected to help reduce the level of ISs.37,38 Finally, the SMART
study was a head-to-head comparison of discrimination algorithms of
various device manufactures and demonstrates that both subcutane-
ous and transvenous ICDs accurately detect the presence of ven-
tricular tachyarrhythmias with sensitivity approaching 100%.39
However, there were marked differences in the specificity of devices
to inhibit therapy for atrial arrhythmias. In addition, the use of dual-
chamber discrimination algorithms incorporating both atrial and ven-
tricular intracardiac signals did not significantly improve specificity for
atrial arrhythmias compared with single-chamber discrimination.
The annualized rate of ISs was estimated to decrease by a factor of
0.76 for each additional year of mean follow-up. A likely factor here is
that some patients are at higher risk of ISs than others. Those at
higher risk tend to have events early in follow-up, leaving a lower risk
group at the later follow-up times. As the model is only looking at the
first event, studies with longer follow-up have lower rates.
Our model-estimated analyses show that most studies observed IS
rates that are in agreement with their expected rates—the rate based
on mean follow-up, when the study was conducted, whether the de-
vice used a subcutaneous or transvenous lead, and whether a VT
zone was programmed. The only study that had a significantly lower
IS rate than expected based on all other study results was PainFree
SST. The low rate of ISs in that study may be attributable to one or
more factors that could not be modelled due to being unique to a sin-
gle study or to incomplete reporting across studies. Factors that may
Study Name
SCD HeFT, 2005
Gonzalez-Enriquez S et al., 2012
Olde Nordkamp LR et al., 2012
S-ICD IDE, 2013
DECREASE-Conventional, 2015
DECREASE-Progressive, 2015
EFFORTLESS, 2015
PainFree SST, 2015
RE Model
0.000 0.050 0.100
Incidence Rate
0.150 0.200
0.059 [ 0.051 , 0.069 ]
0.064 [ 0.053 , 0.077 ]
0.045 [ 0.023 , 0.090 ]
0.073 [ 0.048 , 0.112 ]
0.062 [ 0.030 , 0.131 ]
0.050 [ 0.022 , 0.111 ]
0.047 [ 0.035 , 0.064 ]
0.052 [ 0.042 , 0.065 ]
0.058 [ 0.053 , 0.063 ]
Annual Appropriate
Shock Rate [95% Cl]
Figure 4 Appropriate shock meta-analysis. Meta-analysis depicting annualized appropriate shock rate within a subgroup of the 16 studies that re-
ported appropriate shocks.
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account for the low rate include the specific discrimination algorithms
the device employs, programming for delayed-detection, patient-
management techniques, or patient risk factors. Recently, Biton et
al.40 reported age as an inverse risk factor for inappropriate therapy
from the MADIT-RIT trial.
To our knowledge, this is the first systematic review and meta-
analysis of appropriate and inappropriate ICD shock rates. Thus, our
findings suggest that a contemporary benchmark for future studies of
ICD performance should be annualized rates of 5.8% for appropriate
shocks and 6.4% for ISs; and one study included in our analysis
(PainFree SST) suggests that a rate of 1 in 50 patients receiving an IS
is achievable. Although the appropriate shock rates were highly uni-
form across studies, IS rates appear to be influenced by factors that
include the technology configuration, device programming, and
rhythm discrimination algorithms. We could not assess patient fac-
tors due to inadequate reporting across studies. Therefore, it is im-
portant that future reports uniformly include these parameters for
comparison.
Limitations
Our study shares similar limitations with previous studies using a simi-
lar methodology. First, there was some heterogeneity in the studies
with respect to inclusion criteria, patient population, and criteria for
ICD implantation. Additionally, co-morbidities and other patient risk
factors which may have influenced the use of a VR-ICD rather than a
DR-ICD cannot be accounted for. However, the relative balance in
the patient characteristics between the VR- and DR- cohort within
each of the selected studies should mitigate this concern. Although
we used a random-effects model to account for some of this vari-
ation, it should be acknowledged that we cannot account for hetero-
geneity completely through this method. In addition, several potential
contributing factors to ISs (i.e. remote monitoring, AF) were not re-
ported for all studies, which prevented estimating the degree of asso-
ciation. This may have contributed to the excess heterogeneity
observed across studies in the IS rates.
Conclusions
A comprehensive review of the literature shows that 6.4% of patients
with ICDs typically experienced a first IS annually, with a strong trend
towards reduction in the most recent years. This is important infor-
mation that should reassure patients and their families, general practi-
tioners, cardiologists, scientific societies, and regulators. Notably, one
of the 16 studies was better than predicted with the lowest reported
rate (1.9%) and could not be explained by timing of the study or
other covariates which emphasizes the need to continue investing in
novel optimization algorithms and modern ICD programming.
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